Quarterly numbers were $127 million vs $121 million consensus for US. Ex-US was $37M vs $21m consensus. MDVN never acknowledges the numbers posted by Astellas. Its fine though. Probably one of the best ideas in Biotech from this level.
$47 is probably a reach, but what I do know if we can assume 12m diluted shares and saving $2.8m in interest and amt is about $0.24 a share pre-tax. Thats relatively significant number on this earnings base. I don't really care about the promotion, if they can get the balance sheet cleaned up like they are doing its a decent underfollowed story.